Rhythm Pharmaceuticals Announces FDA Approval of IMCIVREE® (Setmelanotide) for Use in Patients with Bardet-Biedl Syndrome
Summary : IMCIVREE now available for chronic weight management in adult and pediatric patients 6 years of age and older with monogenic…